hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang上一页:癫痫患者手术评估新型工具
- 2022-05-04上海医疗机构率先成功为小年龄儿童完成Wada检验
- 2022-04-2720120905央视健康之路:张晋讲大蒜的药用价值
- 2022-04-13上海率先探索异地就医门诊费直接结算
- 2022-04-12癫痫发作对中风患者静脉溶栓的长期转移有效
- 2022-04-11预测癫痫患者再入院风险
- 2022-04-11药学版元宵灯谜 看你能猜对几个问题
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 预测癫痫患者再入院风险
- 药学版元宵灯谜 看你能猜对几个问题
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 控制癫痫患者再次抽搐,不包括可选药物?
- 综述:癫痫持续状态诊治最新进展
- 癫痫猝死:凶手是谁?
- 抗癫痫药物预防新发癫痫:任重而道远
- 儿童癫痫的早期症状 癫痫的原因
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- 美国神经病学协会的新指南帮助医生HIV癫痫药物更适合患者
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 不注意这些问题,吃多少药都没用!
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- UCB的Vimpat癫痫新适应症在美国获批
- 2015 神经系统疾病诊疗进展
- 月经期间要注意 有些药物和食物不能食用
- 三庚酸酯可治疗1型转运体缺陷综合征
- 心理百科:春节期间小心疾病
- 癫痫治疗障碍仍难以克服
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 2013国际抗癫痫联合会抗癫痫药用指南
- 癫痫患者手术评估新型工具
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- FDA批准Aptiom用于治疗患者癫痫发作
- Medpage Today:不同类型的抗癫痫药物更有利
- 预防妇女癫痫的关键
- 苏州举办-药企实验室(研发/QC)规范管理与 ICH 指南 及药品最新进展」研修班
- 孕妇能吃饭味精吗 食用味精过度危害大(2)
- 痫病如何用药 3大方法用药癫痫病
- Medpage Today:不同都可抗癫痫药物的联用更有利
- 卫材在德国推出新一代抗癫痫药Fycompa
- 20130821山东卫视养生:许新升谈癫痫的危害
- 一种特异性的癫痫猝死类型【视频】
- 经典病例判别:手把手教你治疗强攻击性患者
- 快速上指头南:惊厥性癫痫持续状态监护与治疗
- 高温瑜伽 应该如何恰当练习高温瑜伽
- 头痛怎么办 4种缓解头痛的法则一定要牢记
- UCB的Vimpat癫痫一新适应症在美国获批
- 头皮脑电图或功能磁共振成像一回合灶性癫痫有定位作用